Clinical trials: Acute Wound
Lung Injury, Acute
The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury
This is an early phase (phase IIa), randomized, multi-center study in subjects with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS).
- Trial name
- NCT01597635
- Testing
- Dose 1 GSK2586881, Dose 2 GSK2586881, Dose 3 GSK2586881
- Where
- 19 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Wound and Injuries, Surgical Wound Dehiscence
The Clinical Efficacy of RENASYS TOUCH NPWT System in the Management of Acute, Sub-acute and Chronic Wounds
The study is looking at the clinical efficacy, functionality and device performance of a new Negative Pressure Wound Therapy (NPWT) system in the management of a variety of wound types, in a real-life clinical setting.
- Trial name
- NPWT (NCT02565043)
- Testing
- RENASYS TOUCH Negative Pressure Wound Therapy System
- Where
- 2 sites in South Africa
- Volunteers
- 80 people
- Sponsor
- Smith & Nephew, Inc.
Traumatic Brain Injury
Sovateltide for the Treatment of Acute Traumatic Brain Injury
Traumatic brain injury (TBI) remains a leading cause of global disability, yet current clinical management is limited to supportive care and pressure stabilization using hyperosmolar therapies like mannitol and hypertonic saline.
- Trial name
- RESTORE-TBI (NCT07861126)
- Testing
- Sovateltide
- Volunteers
- 214 people
- Sponsor
- Pharmazz, Inc.
Acute Kidney Injury, Renal Insufficiency
Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography
Contrast-induced acute kidney injury (CI-AKI) has been recognized as the third most common cause of hospital acquired AKI, after hypotension-associated hypo-perfusion and post-operative AKI.
- Conditions
- Acute Kidney Injury, Renal Insufficiency, Kidney Diseases
- Trial name
- NORDICA (NCT02263820)
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Sapere Bio
Acute Radiation Syndrome
A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011
This trial is designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic of KMRC011 injection in healthy adult volunteers.
- Trial name
- NCT03585803
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Intron Biotechnology, Inc.
Ankle Sprain
Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain
To demonstrate the therapeutic efficacy of a generic diclofenac epolamine patch against Flector patch in the treatment of pain in subjects with minor ankle sprain
- Trial name
- NCT02324270
- Testing
- Diclofenac epolamine
- Where
- 31 sites in United States
- Volunteers
- 658 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Acute Kidney Injury, Septic Shock
Targeting Abdominal Perfusion Pressure in Septic Shock
A randomized control trial among patients with septic shock, studying the incidence, progression and recovery of AKI.
- Conditions
- Acute Kidney Injury, Septic Shock, Resuscitations
- Trial name
- MAP-APP (NCT03582046)
- Testing
- Abdominal Perfusion Pressure (APP), Mean Arterial Pressure (MAP)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Potrero Medical
Acute Kidney Injury
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
The purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute kidney injury (AKI).
- Trial name
- NCT01400893
- Testing
- SCD
- Where
- 26 sites in United States
- Volunteers
- 134 people
- Sponsor
- SeaStar Medical
Head Trauma,Closed
International Trial of Efficacy of Cytoflavin in Head Trauma
The study will access the efficacy and safety of treatment with CITOFLAVIN® in patients with non-penetrating moderately severe traumatic brain injury (TBI).
- Trial name
- MITRA (NCT04631484)
- Testing
- Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)
- Where
- 8 sites in Kazakhstan, Russia
- Volunteers
- 166 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Acute Respiratory Distress Syndrome (ARDS), ARDS
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress…
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT06701656
- Testing
- Cohort C: bevacizumab
- Where
- 41 sites in United States
- Volunteers
- 200 people
- Sponsor
- PPD Development, LP
Sepsis, Acute Lung Injury
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
This Phase I/IIa, multi-center, randomized, placebo-controlled, single-blinded dose-escalation study evaluated TNX-832 (also referred to as ALT-836 and Sunol cH36) in subjects with suspected or proven bacteria-induced ALI/ARDS.
- Conditions
- Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
- Trial name
- NCT01438853
- Testing
- TNX-832
- Where
- 7 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Altor BioScience
Acute Respiratory Distress Syndrome (ARDS), ARDS
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress…
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT06701669
- Testing
- Cohort B: paridiprubart
- Where
- 41 sites in United States
- Volunteers
- 200 people
- Sponsor
- PPD Development, LP
Acute Aortic Dissection, Aortic Rupture
Thoraflex Hybrid Post-Market Study
This is a global, prospective non-interventional, multi-centre, post-market study of the Vascutek Thoraflex™ Hybrid system in patients with acute thoracic aortic syndrome, subacute/chronic dissection of the aorta and aortic…
- Conditions
- Acute Aortic Dissection, Aortic Rupture, Penetrating Aortic Ulcer, Aortic Dissection
- Trial name
- THOR (NCT03414866)
- Testing
- EQ-5D-5L QOL questionnaire
- Where
- 7 sites in Canada, Germany and 2 more
- Volunteers
- 182 people
- Sponsor
- Vascutek Ltd.
Covid19, Stage 1 Acute Kidney Injury
Phase 2a MIB-626 vs. Placebo COVID-19
The proposed phase 2a trial will determine whether MIB-626 treatment in adults with COVID-19 infection and stage 1 acute kidney injury is more efficacious than placebo in preventing worsening of kidney function, as assessed by…
- Trial name
- NCT05038488
- Testing
- MIB-626, Home Treatment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Metro International Biotech, LLC
Acute Kidney Injury
Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
This trial will evaluate whether treatment with CRMD001 (unique formulations of the iron chelator, Deferiprone) will reduce morbidity and mortality in subjects with Chronic Kidney Disease (CKD) and additional risk factors.
- Trial name
- NCT01391520
- Testing
- deferiprone
- Sponsor
- CorMedix Therapeutics
Acute Spinal Cord Injury
Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
This study is non-randomized, multicenter, confirmatory study by intrathecal administration of KP-100IT, code of HGF (Hepatocyte Growth Factor ) formulation for intrathecal injection, in subjects with acute spinal cord injury.
- Trial name
- NCT04475224
- Testing
- KP-100IT
- Where
- 5 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Kringle Pharma, Inc.
Acute Myocardial Infarctus
Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction
Objectives of the phase 2 prospective, multicenter, randomized, double-blind, placebo-controlled study is to assess safety and efficacy of TRO40303 administered just before balloon inflation during percutaneous coronary…
- Trial name
- NCT01374321
- Testing
- TRO40303
- Where
- 11 sites in Denmark, France and 2 more
- Volunteers
- 168 people
- Sponsor
- Hoffmann-La Roche
Spinal Cord Injury (SCI)
Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)
Acute Spinal Cord Injury (SCI) is a rare injury that leads to permanent neuromotor impairment and sudden disability. Approximately 25,000 people experience cervical SCI in the United States, Europe, and Japan every year.
- Trial name
- ELASCI (NCT04295538)
- Testing
- Elezanumab
- Where
- 41 sites in United States, Australia and 5 more
- Volunteers
- 60 people
- Sponsor
- AbbVie
Acute Kidney Injury
A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI
The purpose of this study is to determine whether recombinant Alkaline Phosphatase (recAP) is effective and save, and to determine the most effective dose, in the treatment of patients with acute kidney injury caused by sepsis.
- Trial name
- STOP-AKI (NCT02182440)
- Testing
- recAP
- Where
- 58 sites in United States, Austria and 9 more
- Volunteers
- 301 people
- Sponsor
- AM-Pharma
Acute Kidney Injury
A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males
This is an exploratory study in a small, well controlled group of healthy subjects to explore the effect of CXA-10 on pravastatin and Vytorin® (combination of simvastatin and ezetimibe).
- Trial name
- DDI (NCT02547402)
- Testing
- CXA-10, pravastatin, Vytorin® (combination of simvastatin and ezetimibe)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Complexa, Inc.